title: Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation.
abstract: BACKGROUND
  Atrial fibrillation (AF) is associated with diffuse left atrial fibrosis and a reduction in endocardial voltage. These changes are indicators of AF severity and appear to be predictors of treatment outcome. In this study, we report the utility of delayed-enhancement magnetic resonance imaging (DE-MRI) in detecting abnormal atrial tissue before radiofrequency ablation and in predicting procedural outcome.
  
  
  RESULTS
  Eighty-one patients presenting for pulmonary vein antrum isolation for treatment of AF underwent 3-dimensional DE-MRI of the left atrium before the ablation. Six healthy volunteers also were scanned. DE-MRI images were manually segmented to isolate the left atrium, and custom software was implemented to quantify the spatial extent of delayed enhancement, which was then compared with the regions of low voltage from electroanatomic maps from the pulmonary vein antrum isolation procedure. Patients were assessed for AF recurrence at least 6 months after pulmonary vein antrum isolation, with an average follow-up of 9.6+/-3.7 months (range, 6 to 19 months). On the basis of the extent of preablation enhancement, 43 patients were classified as having minimal enhancement (average enhancement, 8.0+/-4.2%), 30 as having moderate enhancement (21.3+/-5.8%), and 8 as having extensive enhancement (50.1+/-15.4%). The rate of AF recurrence was 6 patients (14.0%) with minimal enhancement, 13 (43.3%) with moderate enhancement, and 6 (75%) with extensive enhancement (P<0.001).
  
  
  CONCLUSIONS
  DE-MRI provides a noninvasive means of assessing left atrial myocardial tissue in patients suffering from AF and might provide insight into the progress of the disease. Preablation DE-MRI holds promise for predicting responders to AF ablation and may provide a metric of overall disease progression.
authors.affiliation: Atrial Fibrillation Program, University of Utah School of Medicine, Salt Lake City, UT 84132-2400, USA.
authors.forename: Robert S
authors.initials: RS
authors.lastname: Oakes
authors.forename: Troy J
authors.initials: TJ
authors.lastname: Badger
authors.forename: Eugene G
authors.initials: EG
authors.lastname: Kholmovski
authors.forename: Nazem
authors.initials: N
authors.lastname: Akoum
authors.forename: Nathan S
authors.initials: NS
authors.lastname: Burgon
authors.forename: Eric N
authors.initials: EN
authors.lastname: Fish
authors.forename: Joshua J E
authors.initials: JJ
authors.lastname: Blauer
authors.forename: Swati N
authors.initials: SN
authors.lastname: Rao
authors.forename: Edward V R
authors.initials: EV
authors.lastname: DiBella
authors.forename: Nathan M
authors.initials: NM
authors.lastname: Segerson
authors.forename: Marcos
authors.initials: M
authors.lastname: Daccarett
authors.forename: Jessiciah
authors.initials: J
authors.lastname: Windfelder
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: McGann
authors.forename: Dennis
authors.initials: D
authors.lastname: Parker
authors.forename: Rob S
authors.initials: RS
authors.lastname: MacLeod
authors.forename: Nassir F
authors.initials: NF
authors.lastname: Marrouche
mesh_terms: D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery*; D017115:Catheter Ablation; D003131:Combined Modality Therapy; D018450:Disease Progression; D005260:Female; D005355:Fibrosis; D006325:Heart Atria / Q000473:pathology / Q000601:surgery; D006801:Humans; D021621:Imaging, Three-Dimensional; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009206:Myocardium / Q000473:pathology*; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents